Aktuellt
SENASTE
Redeye comments on SenzaGen’s directed issue, raising SEK37.2m before issue-related costs. We argue the capital injection is solid as it intends to finance activities to accelerate the company’s future growth and strengthen the shareholder list. Furthermore, we adjust our fair value range according to the announcement, resulting in an updated diluted base case.
LÄS MER
